Statin therapy is associated with lower prevalence of gut microbiota dysbiosis
Artikel i vetenskaplig tidskrift, 2020
Microbiome community typing analyses have recently identified the Bacteroides2 (Bact2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans1,2. Bact2 is characterized by a high proportion of Bacteroides, a low proportion of Faecalibacterium and low microbial cell densities1,2, and its prevalence varies from 13% in a general population cohort to as high as 78% in patients with inflammatory bowel disease2. Reported changes in stool consistency3 and inflammation status4 during the progression towards obesity and metabolic comorbidities led us to propose that these developments might similarly correlate with an increased prevalence of the potentially dysbiotic Bact2 enterotype. Here, by exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of the cross-sectional MetaCardis Body Mass Index Spectrum cohort (n = 888), we identify statin therapy as a key covariate of microbiome diversification. By focusing on a subcohort of participants that are not medicated with statins, we find that the prevalence of Bact2 correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. Systemic inflammation levels in Bact2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of Bact2 as a dysbiotic microbiome constellation. We also observe that obesity-associated microbiota dysbiosis is negatively associated with statin treatment, resulting in a lower Bact2 prevalence of 5.88% in statin-medicated obese participants. This finding is validated in both the accompanying MetaCardis cardiovascular disease dataset (n = 282) and the independent Flemish Gut Flora Project population cohort (n = 2,345). The potential benefits of statins in this context will require further evaluation in a prospective clinical trial to ascertain whether the effect is reproducible in a randomized population and before considering their application as microbiota-modulating therapeutics.
Författare
Sara Vieira-Silva
KU Leuven
Gwen Falony
KU Leuven
Eugeni Belda
Université Pierre et Marie Curie (UPMC)
Trine Nielsen
Köpenhamns universitet
Judith Aron-Wisnewsky
Université Pierre et Marie Curie (UPMC)
Rima Chakaroun
Universität Leipzig
Sofia K. Forslund
Max Delbrueck Centrum Fuer Molekulare Medizin
Karen Assmann
Université Pierre et Marie Curie (UPMC)
Mireia Vallès-Colomer
KU Leuven
Thi Thuy Duyen Nguyen
KU Leuven
Sebastian Proost
KU Leuven
Edi Prifti
Université Pierre et Marie Curie (UPMC)
Valentina Tremaroli
Wallenberg Lab.
Nicolas Pons
Université Paris-Saclay
Emmanuelle Le Chatelier
Université Paris-Saclay
Fabrizio Andreelli
Université Pierre et Marie Curie (UPMC)
Jean-Phillippe Bastard
Assistance publique – Hôpitaux de Paris (AP-HP)
Luis P. Coelho
European Molecular Biology Laboratory
Nathalie Galleron
Université Paris-Saclay
Tue H. Hansen
Köpenhamns universitet
Jean-Sébastien Hulot
Assistance publique – Hôpitaux de Paris (AP-HP)
Christian Lewinter
Köpenhamns universitet
Helle K. Pedersen
Köpenhamns universitet
Benoit Quinquis
Université Paris-Saclay
Christine Rouault
Université Pierre et Marie Curie (UPMC)
Hugo Roume
Université Paris-Saclay
Joe-Elie Salem
Assistance publique – Hôpitaux de Paris (AP-HP)
Nadja B. Søndertoft
Köpenhamns universitet
Sothea Touch
Université Pierre et Marie Curie (UPMC)
Renato Alves
European Molecular Biology Laboratory
Chloe Amouyal
Université Pierre et Marie Curie (UPMC)
Ehm Astrid Andersson Galijatovic
Köpenhamns universitet
Olivier Barthelemy
Assistance publique – Hôpitaux de Paris (AP-HP)
Jean-Paul Batisse
Assistance publique – Hôpitaux de Paris (AP-HP)
Magalie Berland
Université Paris-Saclay
Randa Bittar
Assistance publique – Hôpitaux de Paris (AP-HP)
Hervé Blottière
Université Paris-Saclay
Frederic Bosquet
Assistance publique – Hôpitaux de Paris (AP-HP)
Rachid Boubrit
Assistance publique – Hôpitaux de Paris (AP-HP)
Olivier Bourron
Assistance publique – Hôpitaux de Paris (AP-HP)
Mickael Camus
Université Paris-Saclay
Dominique Cassuto
Assistance publique – Hôpitaux de Paris (AP-HP)
Cecile Ciangura
Assistance publique – Hôpitaux de Paris (AP-HP)
Jean-Philippe Collet
Assistance publique – Hôpitaux de Paris (AP-HP)
Maria-Carlota Dao
Université Pierre et Marie Curie (UPMC)
Jean Debedat
Université Pierre et Marie Curie (UPMC)
Morad Djebbar
Assistance publique – Hôpitaux de Paris (AP-HP)
Angélique Doré
Université Paris-Saclay
Line Engelbrechtsen
Köpenhamns universitet
Soraya Fellahi
Assistance publique – Hôpitaux de Paris (AP-HP)
Sebastien Fromentin
Université Paris-Saclay
Philippe Giral
Assistance publique – Hôpitaux de Paris (AP-HP)
Marianne Graine
Integromics Unit
Agnes Hartemann
Assistance publique – Hôpitaux de Paris (AP-HP)
Bolette Hartmann
Köpenhamns universitet
Gerard Helft
Assistance publique – Hôpitaux de Paris (AP-HP)
Serge Hercberg
U1153 INSERM
Malene Hornbak
Köpenhamns universitet
Richard Isnard
Assistance publique – Hôpitaux de Paris (AP-HP)
Sophie Jaqueminet
Assistance publique – Hôpitaux de Paris (AP-HP)
Niklas Rye Jørgensen
Köpenhamns universitet
Hanna Julienne
Université Paris-Saclay
Johanne Justesen
Köpenhamns universitet
Judith Kammer
Universität Leipzig
Mathieu Kerneis
Assistance publique – Hôpitaux de Paris (AP-HP)
Jean Khemis
Assistance publique – Hôpitaux de Paris (AP-HP)
Nikolaj Krarup
Köpenhamns universitet
Michael Kuhn
European Molecular Biology Laboratory
Aurélie Lampuré
Université Pierre et Marie Curie (UPMC)
Véronique Lejard
Université Paris-Saclay
Florence Levenez
Université Paris-Saclay
Lea Lucas-Martini
Assistance publique – Hôpitaux de Paris (AP-HP)
Robin Massey
Université Paris-Saclay
Nicolas Maziers
Université Paris-Saclay
Jonathan Medina-Stamminger
Assistance publique – Hôpitaux de Paris (AP-HP)
Lucas Moitinho-Silva
European Molecular Biology Laboratory
Gilles Montalescot
Assistance publique – Hôpitaux de Paris (AP-HP)
Sandrine Moutel
Assistance publique – Hôpitaux de Paris (AP-HP)
Laetitia Pasero Le Pavin
Université Paris-Saclay
Christine Poitou-Bernert
Université Pierre et Marie Curie (UPMC)
Francoise Pousset
Assistance publique – Hôpitaux de Paris (AP-HP)
Laurence Pouzoulet
Assistance publique – Hôpitaux de Paris (AP-HP)
Sebastian Schmidt
European Molecular Biology Laboratory
Johanne Silvain
Assistance publique – Hôpitaux de Paris (AP-HP)
Mathilde Svendstrup
Köpenhamns universitet
Timothy Swartz
Université Pierre et Marie Curie (UPMC)
Thierry Vanduyvenboden
Université Paris-Saclay
Camille Vatier
Assistance publique – Hôpitaux de Paris (AP-HP)
Eric Verger
Université Pierre et Marie Curie (UPMC)
Stefanie Walther
Universität Leipzig
Marc-Emmanuel Dumas
Imperial College London
Stanislav Dusko Ehrlich
Université Paris-Saclay
Pilar Galan
U1153 INSERM
Jens P. Gøtze
Köpenhamns universitet
Torben Hansen
Köpenhamns universitet
Jens Juul Holst
Köpenhamns universitet
Lars Køber
Köpenhamns universitet
Ivica Letunic
Biobyte Solutions
Jens B Nielsen
Chalmers, Biologi och bioteknik, Systembiologi
Jean-Michel Oppert
Assistance publique – Hôpitaux de Paris (AP-HP)
M. Stumvoll
Universität Leipzig
H. Vestergaard
Köpenhamns universitet
Jean-Daniel Zucker
Université Pierre et Marie Curie (UPMC)
Peer Bork
European Molecular Biology Laboratory
O. B. Pedersen
Köpenhamns universitet
Fredrik Bäckhed
Köpenhamns universitet
K. Clement
Université Pierre et Marie Curie (UPMC)
Jeroen Raes
KU Leuven
Nature
0028-0836 (ISSN) 1476-4687 (eISSN)
Vol. 581 7808 310-315Ämneskategorier
Bioinformatik och systembiologi
DOI
10.1038/s41586-020-2269-x
PubMed
32433607